Clinical trials: Psychological Disorders
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250627
- Testing
- Saredutant succinate (SR48968C)
- Where
- 8 sites in Canada, Chile and 6 more
- Volunteers
- 465 people
- Sponsor
- Sanofi
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Aging, Cognitive Change
Test and Usability of Mixed-reality Screening Tool for Early Detection of Cognitive Declines
The aim of this study as part of the SCOBES-AR project is to establish and test a protocol for implementation and usability of mixed reality-enhanced multidisciplinary screening tool for early detection of cognitive impairments…
- Trial name
- SCOBES-AR (NCT05403814)
- Testing
- observational screening procedure (no intervention)
- Where
- Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Alzheimer Disease, Dementia
A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease
The purpose of this study is to collect and compare information regarding the treatment and outcome of patients diagnosed with Alzheimer's disease who are receiving either drug or nondrug treatment.
- Conditions
- Alzheimer Disease, Dementia, Nervous System Diseases, Mental Disorders
- Trial name
- NCT00291421
- Volunteers
- 2,360 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Erectile Dysfunction
Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin
The purpose of this study is to see if avanafil causes any changes in blood pressure and pulse rate when taken with doxazosin or tamsulosin.
- Trial name
- NCT01100021
- Testing
- Tamsulosin and avanafil, Doxazosin and avanafil
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Post-Traumatic Stress Disorder
A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)
The purpose of the present study is to evaluate the safety and efficacy of Brainsway Deep TMS (DTMS) for the treatment of PTSD.
- Trial name
- NCT02479906
- Testing
- Deep TMS System
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 203 people
- Sponsor
- Brainsway
Posttraumatic Stress Disorder
Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with at least severe PTSD.
- Trial name
- NCT03485287
- Testing
- Midomafetamine HCl, Manualized therapy
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Resilient Pharmaceuticals
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Healthy Smokers
Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations
The purpose of this study is to determine the pharmacokinetic profile of nicotine following a single oral administration of three new nicotine lozenge formulations (V0474) in comparison with two reference products.
- Trial name
- NCT01574898
- Testing
- V0474 - A mg, V0474 - B mg, V0474 - C mg
- Where
- France
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Mild Cognitive Impairment, Early Alzheimer's Disease
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
The purpose of this study is to determine whether daily treatment with this new treatment approach, called COT would be effective in protecting the memory and brain regions of people who are already showing signs of memory loss.
- Conditions
- Mild Cognitive Impairment, Early Alzheimer's Disease, Memory Impairment
- Trial name
- NCT05122598
- Testing
- COT
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Evon Medics LLC
Anxiety Disorder
GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)
This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.
- Trial name
- NCT00546624
- Testing
- MK0777
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Postpartum Depression
Efficacy of MI078 Capsules in Treating Postpartum Depression
This study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants.
- Trial name
- NCT06963580
- Testing
- MI078 capsule dose 1, MI078 capsule dose 2
- Where
- 21 sites in China
- Volunteers
- 72 people
- Sponsor
- Nanjing Minova Pharmaceutical Co., Ltd.
Alzheimer's Disease
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
Brief summary: This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of AD-35 tablet in patients with mild to moderate Alzheimer's Disease.
- Trial name
- WAY (NCT03790982)
- Testing
- AD-35 60 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Alzheimer's Disease
Alzheimer's Disease Long-term Follow-up Study (ALF Study)
Open study for efficacy and safety of donepezil treatment during 48 weeks
- Trial name
- NCT00165724
- Testing
- Donepezil Hydrochloride
- Where
- 7 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- Eisai Korea Inc.
Autism, Autism Spectrum Disorder
Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism
The goal of this clinical trial is to determine whether cannabidiol (CBD, 28%) combined with terpenes and a small amount of THC (1%) can help reduce symptoms of autism, and to evaluate the safety of this treatment.
- Trial name
- TECA (NCT07199218)
- Testing
- Terpenes-Enriched CBD-Predominant Oil, Terpenes-Enriched CBD Oil (THC-Free)
- Where
- Israel
- Volunteers
- 78 people
- Sponsor
- Bazelet Nehushtan LtD.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Attention Deficit Hyperactivity Disorder (ADHD)
Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary study objective is to evaluate the efficacy of Vayarin in ADHD adults.
- Trial name
- NCT02257216
- Testing
- Vayarin®
- Where
- 4 sites in United States
- Volunteers
- 171 people
- Sponsor
- Enzymotec
Depression, Bipolar
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
This is an 8-week, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of aripiprazole as an adjunctive treatment with mood stabilizer for the treatment of patients (outpatients or…
- Trial name
- APOLLO (NCT03423680)
- Testing
- Abilify 2, 5, 10, 15mg (Tablet)
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder, Depression
Individual Patient Esmethadone (REL-1017) Expanded Access Program
To provide expanded access of esmethadone (REL-1017) to patients with a serious or immediately life-threatening disease or condition that may potentially benefit from esmethadone (REL-1017) who do not have access to other…
- Trial name
- NCT06009003
- Testing
- REL-1017
- Sponsor
- Relmada Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.